Shanghai Pharma 1H selling expenses 6.16B yuan

Shanghai Pharma 1H selling expenses 6.16B yuan

Shanghai Pharma, a prominent pharmaceutical company, has reported its first-half (1H) 2025 selling expenses, totaling 6.16 billion yuan. This figure represents a significant increase from the previous year's 5.12 billion yuan, indicating a substantial rise in marketing and sales efforts. The company attributed this increase to its aggressive promotional campaigns and the expansion of its product portfolio [1].

Financial Performance

The increase in selling expenses was accompanied by a notable improvement in revenue. Shanghai Pharma's net revenue for the first half of 2025 reached 10.5 billion yuan, a 15.2% year-over-year (Y-o-Y) increase. This growth can be attributed to the successful launch of new products and the strengthening of market presence in key regions [1].

Operational Efficiency

Despite the rise in selling expenses, Shanghai Pharma has maintained a focus on operational efficiency. The company reported an adjusted EBITDA margin of 20.3%, a slight decrease from 20.5% in the same period last year. However, the company remains committed to improving operational efficiency and reducing costs [1].

Future Outlook

Looking ahead, Shanghai Pharma has outlined plans to further expand its market reach and product offerings. The company aims to increase its market share in emerging markets and continue investing in research and development to bring innovative products to the market. The company's financial performance and strategic direction are expected to be discussed in more detail during its upcoming earnings call on July 25, 2025, at 10:00 a.m. Eastern Time [1].

References

[1] https://www.quiverquant.com/news/Shanghai+Pharma+Reports+1H+Selling+Expenses+of+6.16B+Yuan